Levetiracetam in clinical use - A prospective observational study

Seizure

Volumn 12, Issue 8, 2003, Pages 613-616

  Bird, Jonathan M ^a   Joseph, Zosia A ^a  

^a FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Epilepsy; Learning disabilities; Levetiracetam

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM;

ADOLESCENT; ADULT; AGED; AGGRESSION; ARTICLE; BEHAVIOR DISORDER; CLINICAL OBSERVATION; CONFUSION; CONTROLLED STUDY; DIPLOPIA; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FEMALE; GENERALIZED EPILEPSY; HALLUCINATION; HEADACHE; HEALTH SERVICE; HUMAN; LEARNING DISORDER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOMNOLENCE; TITRIMETRY; TREATMENT OUTCOME; VERTIGO;

EID: 0344668605     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1059-1311(03)00143-2     Document Type: Article

References (10)

1. Klitgaard, H. et al. Evidence for a unique profile of levetiracetam in rodent models of seizure and epilepsy. European Journal of Pharmacology 1998; 353: 191-206.
2. Loscher, W., Honack, D. and Rundfeldt, C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (UCB LO59) in the kindling model of temporal lobe epilepsy. The Journal of Pharmacology and Experimental Therapeutics 1998; 284: 474-479.
3. Ben-Menachem, E. and Falter, U. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial seizures: a multicentre, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41: 1276-1283.
4. Cereghino, J. J., Biton, V., Abou-Khalil, B., Dreifuss, F., Gauer, L. J., Leppik, I. and the United States Levetiracetam Study Group. Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-242.
5. Shorvon, S. D. and Löwenthal, A. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179-1186.
6. Privitera, M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia 2001; 42: 31-35.
7. Harden, C. Safety profile of levetiracetam. Epilepsia 2001; 42: 36-39.
8. Krakow, K., Waker, M., Otoul, C. and Sander, J. W. A. S. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001; 56: 1772-1774.
9. Betts, T., Waegemans, T. and Crawford, P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80-87.
10. Smith, K., Betts, T. and Pritchett, L. Levetiracetam, a promising option for the treatment of juvenile myoclonic epilepsy. Epilepsia 2000; 41: 39.